Julie Krop compensation by year
DiaMedica Therapeutics Summary Compensation Table · the one fiscal year held| Component | FY2025 |
|---|---|
| Salary | $198,980 |
| Bonus | $0 |
| Stock awards | $0 |
| Option awards | $1,421,100 |
| Non-equity incentive | $79,592 |
| Pension and deferred compensation | $0 |
| All other | $7,891 |
| Total | $1,707,563 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: DiaMedica Therapeutics Inc. DEF 14A filed April 1, 2026, accession 0001437749-26-010879, and prior-year filings. Open the filing on EDGAR.
DiaMedica Therapeutics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Rick Pauls | President and Chief Executive Officer | $2,727,350 |
| Julie Krop · this page | Chief Medical Officer | $1,707,563 |
| Scott Kellen | Chief Financial Officer and Secretary | $1,229,520 |
The full DiaMedica Therapeutics compensation record
free company briefThis page is one person within DiaMedica Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order DiaMedica Therapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are DiaMedica Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Velarion Pro: every company page, peer tools and exports, one seat